Alembic receives EIR for oncology injectable formulation facility at Panelav

This was a pre-approval inspection to cover our Oncology Injectable drug products for which ANDAs were filed with USFDA

High demand leaves Ozempic compensating for Wegovy’s supply shortage: GlobalData

Akums partners with Leiutis and Biophore for developing products for multiple therapies

The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas

Alembic receives USFDA final approval for Nifedipine Extended-Release Tablets

Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022

Eugia Pharma receives USFDA approval for Amphotericin B Liposome for Injection

The product is expected to be launched by Q4 FY23.

Strides receives USFDA approval for Potassium Chloride Oral Solution

The approval further strengthens the Potassium Chloride franchise for the company.

Glenmark launches Zita D for adults with Type 2 diabetes having comorbidities

A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities

CHMP recommends conditional marketing authorization for Spesolimab for generalized pustular psoriasis flares

CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in

Universal COVID-19 vaccine can be game-changer for developing countries like India, says GlobalData

The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.

Glenmark launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in adults

Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).